Hiroyuki Izutsu
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4).
Journal: Modern rheumatology
Published: December 02, 2021
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.
Journal: Modern rheumatology
Published: May 21, 2021
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Journal: Arthritis research & therapy
Published: February 24, 2021
Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.
Journal: Pharmacology research & perspectives
Published: December 04, 2020
Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan.
Journal: Rheumatology and therapy
Published: November 11, 2020
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Journal: Modern rheumatology
Published: October 14, 2020
Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis.
Journal: British journal of clinical pharmacology
Published: June 29, 2020
Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Journal: Arthritis research & therapy
Published: June 25, 2020
Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials.
Journal: Expert opinion on pharmacotherapy
Published: April 30, 2020
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Journal: Arthritis research & therapy
Published: August 06, 2019
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Journal: Annals of the rheumatic diseases
Published: January 31, 2019
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Journal: Annals of the rheumatic diseases
Published: January 31, 2019
Showing 1-12 of 12
Last Updated: 09/26/2026